Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call
Celcuity (Nasdaq: CELC), a clinical-stage biotechnology company focused on developing targeted oncology therapies, has announced the timing for its Q1 2025 financial results release. The company will release its results after market close on Wednesday, May 14, 2025, followed by a management-hosted webcast and conference call at 4:30 p.m. Eastern Time. Domestic participants can dial 1-800-717-1738, while international callers should use 1-646-307-1865. A live webcast will be available, and a replay will be accessible on Celcuity's website after the event.
Celcuity (Nasdaq: CELC), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di terapie oncologiche mirate, ha annunciato la data di pubblicazione dei suoi risultati finanziari del primo trimestre 2025. I risultati saranno diffusi dopo la chiusura del mercato, mercoledì 14 maggio 2025, seguiti da una webcast e una conference call condotte dalla direzione alle 16:30 ora della costa orientale. I partecipanti nazionali possono chiamare il numero 1-800-717-1738, mentre i chiamanti internazionali devono utilizzare il numero 1-646-307-1865. Sarà disponibile una webcast dal vivo e una registrazione sarà accessibile sul sito web di Celcuity dopo l'evento.
Celcuity (Nasdaq: CELC), una empresa biotecnológica en etapa clínica enfocada en desarrollar terapias oncológicas dirigidas, ha anunciado la fecha para la publicación de sus resultados financieros del primer trimestre de 2025. La compañía publicará sus resultados después del cierre del mercado el miércoles 14 de mayo de 2025, seguido de una webcast y una llamada conferencia dirigidas por la gerencia a las 4:30 p.m., hora del este. Los participantes nacionales pueden marcar 1-800-717-1738, mientras que los internacionales deben usar 1-646-307-1865. Habrá una webcast en vivo disponible y una repetición accesible en el sitio web de Celcuity después del evento.
Celcuity (나스닥: CELC)는 표적 항암 치료제 개발에 주력하는 임상 단계 생명공학 회사로, 2025년 1분기 재무 결과 발표 일정을 발표했습니다. 회사는 2025년 5월 14일 수요일 시장 마감 후 결과를 발표하며, 이어서 경영진 주최의 웹캐스트와 컨퍼런스 콜이 동부 표준시 오후 4시 30분에 진행됩니다. 국내 참가자는 1-800-717-1738번으로 전화할 수 있으며, 해외 참가자는 1-646-307-1865번을 이용해야 합니다. 라이브 웹캐스트가 제공되며, 행사 후 Celcuity 웹사이트에서 다시보기를 이용할 수 있습니다.
Celcuity (Nasdaq : CELC), une société biotechnologique en phase clinique spécialisée dans le développement de thérapies oncologiques ciblées, a annoncé la date de publication de ses résultats financiers du premier trimestre 2025. La société publiera ses résultats après la clôture du marché le mercredi 14 mai 2025, suivis d'une webdiffusion et d'une conférence téléphonique animées par la direction à 16h30 heure de l'Est. Les participants nationaux peuvent composer le 1-800-717-1738, tandis que les appelants internationaux doivent utiliser le 1-646-307-1865. Une webdiffusion en direct sera disponible, et un replay sera accessible sur le site web de Celcuity après l'événement.
Celcuity (Nasdaq: CELC), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung zielgerichteter Krebstherapien spezialisiert hat, hat den Termin für die Veröffentlichung seiner Finanzergebnisse für das erste Quartal 2025 bekannt gegeben. Das Unternehmen wird die Ergebnisse nach Börsenschluss am Mittwoch, den 14. Mai 2025 veröffentlichen, gefolgt von einem von der Geschäftsleitung geleiteten Webcast und einer Telefonkonferenz um 16:30 Uhr Eastern Time. Inländische Teilnehmer können die Nummer 1-800-717-1738 wählen, internationale Anrufer verwenden bitte 1-646-307-1865. Ein Live-Webcast wird verfügbar sein, und eine Aufzeichnung wird nach der Veranstaltung auf der Website von Celcuity zugänglich sein.
- None.
- None.
MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2025 after the market closes on Wednesday, May 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Webcast and Conference Call Information
To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1715314&tp_key=61a8c66165. A replay of the webcast will be available on the Celcuity website following the live event.
About Celcuity
Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently recruiting patients. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and Twitter.
View source version of release on GlobeNewswire.com
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123
ICR Healthcare
Patti Bank, patti.bank@icrhealthcare.com
(415) 513-1284
FAQ
When will Celcuity (CELC) release its Q1 2025 earnings?
What time is Celcuity's Q1 2025 earnings call?
How can I access Celcuity's Q1 2025 earnings call?
What does Celcuity (CELC) do as a company?
